Xeophin

Xeophin

Created using Figma
Created using Figma
Xeophin has devised a funding route for developing XeRA - 1 Therapeutic for Rheumatoid Arthritis, but this provision far surpasses the promising medicinal interest. Zeofilin 's unique approach to biotech' s financing can change the paradigm of medical financing. Xeophin tokenizes 50% of the future royalties generated by XeRA - 1, funds its token owner, and benefits from its success. Our mission is to adopt our core technology and promote them through the 6 step process. The result is a transaction-aware IP protection technology portfolio and is tokenized. Later, Xeophin will provide value to the XeRA - 1 token owner and conduct commercialization activities to achieve a significant royalty agreement. The XERA1 token supported by the physical asset, XeRA-1 arthritis remedy, may rise in value when a milestone is hit on a commercial road. If you are alive, the token holder will get cash loyalty payments that match the income of XeRA - 1.
Risk: High
Aug 20, 2018
Feb 22, 2019
46% completed
Raised funds - no Data
ongoing
Token Details
Accepted Currencies
ETH, BTC, FIAT
Company Details
Registered Country
Australia
Additional Details
KYC
Yes
Categories
Platform

About Xeophin

Xeophin Pt y Ltd is a Melbourne, Australia based, Biotech Company with a focus on imunomodulating technologies, and is commit ted to the research, development and commercialisation of new and novel medical treatment s, in a number of high grow th therapeutic areas such as inflammation.

Our mission and vision are simple: “Take our core technologies and drive them through our six step process. The outcome being a transaction ready and IP protected technolog y por t folio. From this Xeophin will under take commercialisation activities to achieve a significant royalt y deal, delivering value to our XeR A-1 Token holders”.

In his position as Chief Executive Of ficer, Troy Neilson brings significant, relevant and recent Biotech experience along with extensive management skills. Travis Molloy as Executive Chairman brings 15 years experience in the development stage Biotech space and governance. Caroline Cook as Non-Executive Director brings to the organisation a wealth of project management, outsourcing and leadership experience.

Xeophin is currently a private and unlisted Australian company. Formal policies and best practice from Corporate Governance to Financial Management have been implemented from inception. Xeophin will reorganise and transition it self into the USA , this entit y is referred to NewCo at this stage. It is the NewCo entit y that will seek SEC compliance and undertake the formal ICO*.

Activity

Posts:
13
VERY LOW
Followers:
27
VERY LOW
Likes:
26
VERY LOW
Followers:
121
VERY LOW
Tweets:
106
MEDIUM
Members:
9 401
HIGH
30 Days Growth:
-455
Alexa
Rank:
11 492 664
VERY LOW
Delta:
0

Team

Verified 0%

Attention. There is a risk that unverified members are not actually members of the team

Travis Molloy Bsc
EXECUTIVE CHAIRMAN
unverified
Troy Neilson
CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR
unverified
Jason Yeates
CHIEF FINANCIAL OFFICER, SENIOR VICE PRESIDENT OF...
unverified
Patrick Mcmanamny
HEAD OF INTELLECTUAL PROPERTY
unverified
Susan Dexter
HEAD OF CMC & GMP
unverified
Caroline Cook
NON-EXECUTIVE DIRECTOR
unverified

Advisors

Verified 0%

Attention. There is a risk that unverified members are not actually members of the team

Goran Ando
CHAIRMAN, CLINICAL ADVISORY COMMITTEE
unverified

Last News

  • Because there may be time differences in information updates, accurate information about each ICO project should be verified through its official website or other communication channels.
  • This information is not a suggestion or advice on investing in ICO funding. Please thoroughly investigate the relevant information yourself and decide on ICO participation.
  • If you think there are issues or problems to be corrected on this content, or if you would like to submit your own ICO project to be listed, Please email us.
Please read the disclaimer and risk warning. Show disclaimer and risk warning.
Planning an ICO? We can help with a wide range of support for all stages of your ICO